8.92
0.33%
-0.05
89bio Inc (ETNB) 最新ニュース
New York State Common Retirement Fund Boosts Stake in 89bio, Inc. (NASDAQ:ETNB) - Defense World
Defense World
Insider Selling: PALEKAR ROHAN, 89bio Inc [ETNB] Chief Executive Officer divested 52718 shares – Knox Daily - Knox Daily
Knox Daily
89bio (NASDAQ:ETNB) Receives Buy Rating from HC Wainwright - MarketBeat
MarketBeat
Cantor Fitzgerald Comments on 89bio, Inc.'s FY2024 Earnings (NASDAQ:ETNB) - Defense World
Defense World
89bio (NASDAQ:ETNB) Trading Up 5.5% - MarketBeat
MarketBeat
89bio, Inc. (NASDAQ:ETNB) to Post FY2024 Earnings of ($2.30) Per Share, Cantor Fitzgerald Forecasts - MarketBeat
MarketBeat
89bio (NASDAQ:ETNB) Price Target Cut to $33.00 by Analysts at Evercore ISI - MarketBeat
MarketBeat
Is it possible to buy 89bio Inc(ETNB) shares at a good price now? – US Post News - US Post News
US Post News
89bio shares target cut to $33 on higher expenses - Investing.com
Investing.com
89bio, Inc. (NASDAQ:ETNB) insider upped their holding by 23% earlier this year - Yahoo New Zealand News
Yahoo New Zealand News
Gaining Ground: 89bio Inc (ETNB) Closes Lower at 8.70, Down -0.11 – DWinneX - The Dwinnex
The Dwinnex
A new trading data show 89bio Inc (ETNB) is showing positive returns. – Sete News - SETE News
SETE News
89bio (NASDAQ:ETNB) Price Target Cut to $29.00 - Defense World
Defense World
BofA Securities's latest rating for ETNB stock – Knox Daily - Knox Daily
Knox Daily
89bio shares target cut, maintains buy rating By Investing.com - Investing.com
Investing.com
89bio (NASDAQ:ETNB) Price Target Lowered to $29.00 at HC Wainwright - MarketBeat
MarketBeat
89bio (NASDAQ:ETNB) Issues Earnings Results - MarketBeat
MarketBeat
(ETNB) Trading Signals - Stock Traders Daily
Stock Traders Daily
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - WICZ
WICZ
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
RBC Capital cuts 89bio shares target on model adjustments - Investing.com
Investing.com
Zurcher Kantonalbank Zurich Cantonalbank Purchases 7692 Shares of 89bio, Inc. (NASDAQ:ETNB) - Defense World
Defense World
Views of Wall Street's Leading Experts on 89bio Inc – Sete News - SETE News
SETE News
New Strong Sell Stocks for January 21st - Yahoo Movies UK
Yahoo Movies UK
Latest Insider moments: PALEKAR ROHAN, 89bio Inc [ETNB] Chief Executive Officer sold 52718 shares – Knox Daily - Knox Daily
Knox Daily
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy - Zacks Investment Research
Zacks Investment Research
All You Need to Know About 89BIO (ETNB) Rating Upgrade to Buy - Yahoo Finance UK
Yahoo Finance UK
89bio, Inc. (NASDAQ:ETNB) insider upped their holding by 23% earlier this year - Yahoo New Zealand News
Yahoo New Zealand News
89bio to Host Key Opinion Leader Webinar on Pegozafermin’s Opportunity in Advanced MASH - ForexTV.com
ForexTV.com
(ETNB) On The My Stocks Page - Stock Traders Daily
Stock Traders Daily
An Analysis of 89bio Inc (ETNB)'s Potential Price Growth – Knox Daily - Knox Daily
Knox Daily
89bio Appoints Biotech Industry Veteran, Martin Babler to its Board of Directors
GlobeNewswire Inc.
89bio adds biotech veteran Martin Babler to board By Investing.com - Investing.com
Investing.com
PRIME Scheme: EMA Says Yes To Hookipa, Bluejay & 89bio But No To Six Others - Pink Sheet
Pink Sheet
89bio signs deal for construction of a production facility in China (NASDAQ:ETNB) - Seeking Alpha
Seeking Alpha
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
89bio CEO Rohan Palekar trades over $620k in company stock - Investing.com
Investing.com
89bio Receives EMA PRIME Status for Pegozafermin in the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) with Fibrosis and Compensated Cirrhosis
GlobeNewswire Inc.
89bio wins EMA priority status for MASH candidate pegozafermin - Pharmaceutical Technology
Pharmaceutical Technology
Madrigal Pharmaceuticals Wins Approval for the First Drug Targeting the Multibillion-Dollar NASH Market. Is the Stock a Screaming Buy?
The Motley Fool
Madrigal’s stock surges as FDA approves first drug for liver disease MASH
MarketWatch
Madrigal Pharmaceuticals gets first FDA approval for drug targeting liver disease MASH
MarketWatch
89bio kicks off Phase III trial for pegozafermin in MASH - Clinical Trials Arena
Clinical Trials Arena
Buffett Loads Up on This Stock Again, Plus CEO Insider Buying - 24/7 Wall St.
24/7 Wall St.
89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying
Benzinga
Over $20M Bet On This Healthcare Stock? Check Out These 3 Stocks Insiders Are Buying - 89bio (NASDAQ:ETNB - Benzinga
Benzinga
Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success
Zacks Investment Research
Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study
Zacks Investment Research
Wall Street Analysts Believe 89BIO (ETNB) Could Rally 121.5%: Here's is How to Trade
Zacks Investment Research
大文字化:
|
ボリューム (24 時間):